search
Back to results

Modular Treatment for Preschool Anxiety

Primary Purpose

Anxiety

Status
Unknown status
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
PIPA
Sponsored by
Adam Lewin
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Anxiety focused on measuring modular, anxiety, preschool, exposure and response prevention, Cognitive behavioral therapy

Eligibility Criteria

3 Years - 7 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Children aged 3 to 7 years
  • Anxiety-based concerns rated as a top problem on the Top Problems Assessment at initial assessment.

Exclusion Criteria:

  • Report or evidence of severe intellectual disability or level 3 autism spectrum disorder (ASD) without accompanying intellectual/language impairment (mild ASD is not exclusionary).
  • Presence of clinical features requiring a higher level of care (inpatient or partial hospital treatment).
  • Unwillingness of parents to accompany their children for multiple study visits;
  • Presence of a significant and/or unstable medical illness that might lead to hospitalization during the study.
  • Initiation of an antidepressant within the 12 weeks preceding study enrollment, antipsychotic within 8 weeks prior to study enrollment, changes in established psychotropic medications within 8 weeks before study enrollment, or any change in alternative medications that might have behavioral effects within 6 weeks prior to study baseline assessment. Youth may remain stable on medications during the study.
  • Ongoing reports of abuse/neglect or trauma reported as a primary concern.
  • Extreme aggression/risk behaviors (e.g., harming animals, fire starting, violence) suggestive of conduct disorder trajectory.

Sites / Locations

  • Rothman Center for Pediatric Neuropsychiatry

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

PIPA

Arm Description

Modularized treatment for anxiety in children ages 3-7 years old

Outcomes

Primary Outcome Measures

Anxiety Improvement as assessed by Clinical Global Impression- Improvement (CGI-I)
7-point clinician rating of improvement of psychopathology

Secondary Outcome Measures

Key Child Problems as assessed by Top Problems Assessment (TPA)
obtains ratings of severity of the top three problems as identified by parent report
Child Diagnostic Presence as measured by the Schedule for Affective Disorders and Schizophrenia for School-Age Children (K-SADS)
Semi-structured diagnostic interview used to assess possible diagnoses via parent report
Anxiety Severity as measured by the Clinical Global Impression- Severity (CGI-S)
7-point clinician rating of severity of psychopathology

Full Information

First Posted
July 15, 2015
Last Updated
April 22, 2020
Sponsor
Adam Lewin
Collaborators
Johns Hopkins All Children's Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT02510391
Brief Title
Modular Treatment for Preschool Anxiety
Official Title
Modular Treatment for Preschool Anxiety
Study Type
Interventional

2. Study Status

Record Verification Date
April 2020
Overall Recruitment Status
Unknown status
Study Start Date
October 2015 (undefined)
Primary Completion Date
March 2020 (Actual)
Study Completion Date
December 2020 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Adam Lewin
Collaborators
Johns Hopkins All Children's Hospital

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This nonrandomized pilot study is investigating the efficacy of a modularized treatment for anxiety in children ages 3-7 years old. Eligibility is determined at a baseline assessment, followed by a second baseline assessment one month later. The treatment protocol, Parent-training Intervention for Preschoolers with Anxiety (PIPA), is flexible and allows for individualized treatments based on a treatment algorithm, ensuring that sessions address the most pressing clinical needs of each child. Treatment consists of weekly 60-minute sessions delivered over the course of 12 weeks. Symptom change is tracked weekly during brief phone assessments and a post-treatment assessment will occur following the final treatment session, approximately 12 weeks after starting treatment. Finally, all participants will complete two follow-up assessments, occurring 1-month and 6-months after the final treatment session.
Detailed Description
Early childhood mental illness is a growing public health concern, and can persist into adolescence and adulthood if left untreated. Anxiety disorders are among the most common psychiatric illnesses in preschool aged youth and place youth at significantly higher risk for anxiety, depression, substance abuse, conduct problems, and diminished academic/occupational and social/relational functioning later in life. Accordingly, there is increasing emphasis on early identification and intervention, before symptoms become entrenched to mitigate a trajectory towards longstanding impairment. Unfortunately, empirically supported treatments for preschoolers with anxiety are limited. The few studies to date have tended to focus on relatively homogeneous samples whose symptoms resemble those in adults (e.g., worries and fears). Anxiety can present in similar ways to adult anxiety, however can also present more broadly in young children. Young children with anxiety may also present with extreme rigidity, sensory hypersensitivity, 'meltdowns'/emotional dysregulation/temper tantrums, ritualistic/routine oriented behavior, and oppositional behavior in some context. By focusing narrowly, treatments have not been adapted for the full range of anxiety presentations in early childhood. Therefore, the proposed study evaluates a modular, parent-driven psychotherapy developed for preschool aged youth (3-7 years) with diagnostic levels of anxiety, as well as anxiety symptoms dimensionally. The treatment program, Parent-training Intervention for Preschoolers with Anxiety (PIPA), is based on empirically supported behavioral and parent-training principles as well as the investigators' recently published pilot study of preschoolers with obsessive compulsive disorder. Sixty youth will be treated during the study. PIPA focuses on exposure and response prevention therapy (E/RP) in the context of behavioral parent training, each of which have efficacy in youth with anxiety, including high functioning autism spectrum disorders (ASD). Certain parenting responses (e.g., overprotection, critical responding, accommodation of anxiety symptoms and avoidance) have been implicated in the etiology and maintenance of pediatric anxiety disorders and, in addition to E/RP, this intervention will target behavioral parent training and unhelpful parenting practices to support long-term outcomes. In addition, this study will investigate one surrogate biomarker of anxiety in young children, fear conditioning (or more specifically, resistance to extinction). Behavioral treatment of anxiety, including the proposed PIPA intervention, relies on principles of extinction. Children and adults with anxiety disorders have been shown to have poorer fear extinction; however, there are few studies in young children examining this phenomenon. The potential to understand fear extinction in young children has implications for improving treatment efficacy and altering the negative trajectory of youth with anxiety disorders. Eligibility will be determined at a baseline assessment. A second baseline assessment will occur one month later for those that qualify. This assessment will be used to control for symptom change due to the natural passage of time. Treatment will be delivered over 12 weeks and will include weekly 60-minute sessions. A brief phone call with an assessor each week will be used to track symptom change during treatment, and a post-treatment assessment will be conducted following the final treatment session, approximately 12 weeks later. Follow-up assessments will occur 1-month and 6-months following the final treatment session.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Anxiety
Keywords
modular, anxiety, preschool, exposure and response prevention, Cognitive behavioral therapy

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
60 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
PIPA
Arm Type
Experimental
Arm Description
Modularized treatment for anxiety in children ages 3-7 years old
Intervention Type
Behavioral
Intervention Name(s)
PIPA
Other Intervention Name(s)
Cognitive behavioral therapy, Exposure and response prevention, Parent training
Intervention Description
Parent-training Intervention for Preschoolers with Anxiety (PIPA) is a behaviorally based modular treatment program for emotional and behavioral problems in young children. 12 sixty minute sessions will be delivered weekly. This intervention employs a modular format following a treatment algorithm in which therapy modules are selected by the therapist and supervisor on a session-by-session basis to address the most pressing clinical needs. Minimum session requirements for parent training/education and fear hierarchy/exposure are set to insure adequate dose of core exposure and response prevention for anxiety across cases.
Primary Outcome Measure Information:
Title
Anxiety Improvement as assessed by Clinical Global Impression- Improvement (CGI-I)
Description
7-point clinician rating of improvement of psychopathology
Time Frame
Rating after the final therapy session, approximately 12 weeks after starting treatment.
Secondary Outcome Measure Information:
Title
Key Child Problems as assessed by Top Problems Assessment (TPA)
Description
obtains ratings of severity of the top three problems as identified by parent report
Time Frame
Assess at end of treatment (approximately 12 weeks from start), 1-month following end of treatment, 6-months after completion of treatment
Title
Child Diagnostic Presence as measured by the Schedule for Affective Disorders and Schizophrenia for School-Age Children (K-SADS)
Description
Semi-structured diagnostic interview used to assess possible diagnoses via parent report
Time Frame
Assess at end of treatment (approximately 12 weeks from start), 1-month following end of treatment, 6-months after completion of treatment
Title
Anxiety Severity as measured by the Clinical Global Impression- Severity (CGI-S)
Description
7-point clinician rating of severity of psychopathology
Time Frame
Assess at end of treatment (approximately 12 weeks from start), 1-month following end of treatment, 6-months after completion of treatment

10. Eligibility

Sex
All
Minimum Age & Unit of Time
3 Years
Maximum Age & Unit of Time
7 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Children aged 3 to 7 years Anxiety-based concerns rated as a top problem on the Top Problems Assessment at initial assessment. Exclusion Criteria: Report or evidence of severe intellectual disability or level 3 autism spectrum disorder (ASD) without accompanying intellectual/language impairment (mild ASD is not exclusionary). Presence of clinical features requiring a higher level of care (inpatient or partial hospital treatment). Unwillingness of parents to accompany their children for multiple study visits; Presence of a significant and/or unstable medical illness that might lead to hospitalization during the study. Initiation of an antidepressant within the 12 weeks preceding study enrollment, antipsychotic within 8 weeks prior to study enrollment, changes in established psychotropic medications within 8 weeks before study enrollment, or any change in alternative medications that might have behavioral effects within 6 weeks prior to study baseline assessment. Youth may remain stable on medications during the study. Ongoing reports of abuse/neglect or trauma reported as a primary concern. Extreme aggression/risk behaviors (e.g., harming animals, fire starting, violence) suggestive of conduct disorder trajectory.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Adam B Lewin, Ph.D., ABPP
Organizational Affiliation
University of South Florida
Official's Role
Principal Investigator
Facility Information:
Facility Name
Rothman Center for Pediatric Neuropsychiatry
City
Saint Petersburg
State/Province
Florida
ZIP/Postal Code
33701
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Modular Treatment for Preschool Anxiety

We'll reach out to this number within 24 hrs